Optimal dialysis treatment differs among kidney disease patients
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a clinical and biochemical syndrome associated with advancing age and characterized by typical symptoms and a deficiency in serum testosterone levels.
Full Post: New recommendations on late-onset hypogonadism
For kidney disease patients who need to undergo dialysis, one type of treatment is not best for all, according to a study appearing in the January 2009 issue of the Journal of the American Society Nephrology (JASN).
The findings indicate that certain patient characteristics should be factored into decisions on whether to choose hemodialysis or peritoneal dialysis.
During hemodialysis, a patient’s blood is allowed to flow through a filter that removes wastes and extra fluids, and the clean blood is then returned to the body. During peritoneal dialysis, a catheter fills a patient’s abdomen with a dialysis solution that draws wastes and extra fluid from the blood into the abdominal cavity; the wastes and fluid are then drained from the body and discarded.
While both dialysis procedures are effective treatments for kidney disease, it is not clear which is best for prolonging patients’ survival. Previous research on this topic has produced conflicting results.
In the United States, peritoneal dialysis is used in a small minority of the dialysis population, usually in younger and healthier patients. In contrast, in Australia and New Zealand up to 40% of dialysis patients receive peritoneal dialysis, making these countries potentially better regions for conducting studies that compare outcomes from hemodialysis and peritoneal dialysis.
To compare the survival rates between patients receiving hemodialysis and those receiving peritoneal dialysis, Stephen McDonald, MD, of the Queen Elizabeth Hospital in Adelaide, Australia, and his colleagues examined data from 25,287 patients in the Australia & New Zealand Dialysis and Transplant Registry who were still receiving dialysis 90 days after entry in the registry.
The researchers found that death rates were significantly lower during the 90 to 365 day period of the study among those being treated with peritoneal dialysis at day 90. However, this effect varied depending on patients’ age and health. Younger patients (<60 years) without other medical conditions had a survival advantage with peritoneal treatment, but other groups did not. Also, after 12 months, the use of peritoneal dialysis at day 90 was associated with significantly increased mortality. This indicates that the results change over time-while peritoneal dialysis might give a survival advantage to some patients in the short term, in the long term it increases patients’ risk of dying compared with hemodialysis.
There are many reasons why one type of dialysis is chosen over another, including quality of life, patient satisfaction, and practice expertise. This study indicates that mortality risks should also be factored into choices between hemodialysis and peritoneal dialysis. For younger patients without other medical conditions, peritoneal dialysis is a reasonable short term therapy, but for other groups, hemodialysis may be a better choice. “Our data suggest caution in the use of peritoneal dialysis in many patients, particularly when this therapy is continued beyond 1 to 2 years,” the authors wrote. However, the researchers noted that their observational study has some inherent limitations, and randomized clinical trials are needed to definitively determine which type of dialysis treatment patients should receive.
For hemodialysis patients, undergoing dialysis for eight hours overnight, three times weekly, reduces the risk of death by nearly 80 percent, compared to conventional, four-hour dialysis, according to research being presented at the American Society of Nephrology’s 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania. In a study led by Ercan Ok, MD, of
Full Post: Overnight hemodialysis dramatically improves survival
Suffering from end-stage renal disease (ESRD), a growing number of patients at the Centre hospitalier de l’Université de Montréal (CHUM), have become the beneficiaries of a North American breakthrough: high efficacy hemodiafiltration (HDF). An extracorporeal blood purification technique, HDF is indicated for ESRD patients. Since the HDF unit was introduced in CHUM’s Nephrology section, preliminary
Full Post: Breakthrough for dialysis patients
A Johns Hopkins study finds that HIV-positive kidney transplant recipients could have the same one-year survival rates for themselves and their donor organs as those without HIV, provided certain risk factors for transplant failure are recognized and tightly managed. “Kidney transplantation is a viable and necessary option for HIV-positive patients with chronic kidney disease, especially
Full Post: Kidney transplant survival can be long-term for people with HIV
A Johns Hopkins transplant surgeon has found strong evidence that women over 45 are significantly less likely to be placed on a kidney transplant list than their equivalent male counterparts, even though women who receive a transplant stand an equal chance of survival. “As woman age, that discrepancy widens to the point where woman over
Full Post: Older women less likely than men to be listed on a kidney transplant list
New Australian research has shown that Indigenous Australians with kidney disease are confused, frustrated and feel poorly informed about their illness. The study reveals Indigenous Australian’s feel inadequately informed and are considerably more uncertain about the cause of their illness compared to non-Indigenous patients with kidney disease. The results of the large qualitative study are
Full Post: Indigenous Australian’s inadequately informed about kidney disease